Sartorius (FRA:SRT3) PT Set at €184.00 by Warburg Research

Sartorius (FRA:SRT3) has been assigned a €184.00 ($213.95) price target by stock analysts at Warburg Research in a research report issued to clients and investors on Monday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the stock. Warburg Research’s target price suggests a potential upside of 3.90% from the stock’s previous close.

SRT3 has been the subject of several other reports. Hauck & Aufhaeuser set a €135.00 ($156.98) target price on Sartorius and gave the stock a “sell” rating in a research report on Friday, August 23rd. Berenberg Bank set a €145.00 ($168.60) target price on Sartorius and gave the stock a “sell” rating in a research report on Thursday, July 25th. HSBC set a €160.00 ($186.05) target price on Sartorius and gave the stock a “neutral” rating in a research report on Wednesday, October 16th. UBS Group set a €184.00 ($213.95) target price on Sartorius and gave the stock a “neutral” rating in a research report on Friday, July 19th. Finally, Deutsche Bank set a €170.00 ($197.67) target price on Sartorius and gave the stock a “neutral” rating in a research report on Tuesday, October 15th. Five equities research analysts have rated the stock with a sell rating and four have given a hold rating to the stock. Sartorius has a consensus rating of “Sell” and an average price target of €147.61 ($171.64).

Sartorius stock opened at €177.10 ($205.93) on Monday. Sartorius has a 1 year low of €71.00 ($82.56) and a 1 year high of €124.70 ($145.00). The business has a 50-day moving average of €170.41 and a 200-day moving average of €172.81.

About Sartorius

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

Further Reading: Diluted Earnings Per Share

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.